French drug company Sanofi announced it's discontinuing research and development for its next-generation mRNA flu vaccine.

A new nasal spray vaccine for H5N1 bird flu has shown promising early results, raising hopes it could one day be used to help ...

Despite Sanofi CEO Paul Hudson’s confidence in vaccines, the French pharma has cut at least one mRNA flu shot program.

Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while holding the potential to provide up to $500 million more in development and ...

UVA Health researchers are advancing a technology that may allow new vaccines to be designed, tested and distributed in weeks ...

A team of researchers in Japan has announced a clinical trial to confirm a vaccine's efficacy against the deadly Nipah virus ...

The first participant in the BRILLIANT 011 first-in-human clinical trial for the HIV vaccine has been enrolled at the Desmond ...

A Nipah virus vaccine developed by the University of Tokyo is set to begin Phase 1 human trials in April, offering hope ...

WHO is monitoring a Nipah virus outbreak in India after two confirmed cases, warning of epidemic risk as vaccine research accelerates amid global surveillance efforts.

Zoonotic vaccines form an essential frontier in infectious disease prevention, bridging the gap between human and animal health. Zoonotic diseases, caused ...